338 related items for PubMed ID: 18611095
1. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease.
Akazawa M, Hayflinger DC, Stanford RH, Blanchette CM.
Am J Manag Care; 2008 Jul; 14(7):438-48. PubMed ID: 18611095
[Abstract] [Full Text] [Related]
2. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM, Akazawa M, Dalal A, Simoni-Wastila L.
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[Abstract] [Full Text] [Related]
3. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
Rascati KL, Akazawa M, Johnsrud M, Stanford RH, Blanchette CM.
Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
[Abstract] [Full Text] [Related]
4. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L, Blanchette CM, Qian J, Yang HW, Zhao L, Zuckerman IH, Pak GH, Silver H, Dalal AA.
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[Abstract] [Full Text] [Related]
5. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
Delea TE, Hagiwara M, Stanford RH, Stempel DA.
Clin Ther; 2008 Mar; 30(3):560-71. PubMed ID: 18405796
[Abstract] [Full Text] [Related]
6. Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy.
Dalal AA, Shah M, D'Souza AO, Crater GD.
Respir Med; 2012 Jun; 106(6):829-37. PubMed ID: 22425138
[Abstract] [Full Text] [Related]
7. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD.
Dalal AA, Candrilli SD, Davis KL.
Manag Care; 2011 Aug; 20(8):46-50, 53-5. PubMed ID: 21887993
[Abstract] [Full Text] [Related]
8. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
Balkissoon R, Make B.
COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
[Abstract] [Full Text] [Related]
9. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
Blais L, Forget A, Ramachandran S.
Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
[Abstract] [Full Text] [Related]
10. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone.
Mapel DW, Nelson LS, Lydick E, Soriano J, Yood MU, Davis KJ.
COPD; 2007 Jun; 4(2):127-34. PubMed ID: 17530506
[Abstract] [Full Text] [Related]
11. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease.
Dalal AA, Roberts MH, Petersen HV, Blanchette CM, Mapel DW.
Int J Chron Obstruct Pulmon Dis; 2010 Dec 31; 6():13-22. PubMed ID: 21311689
[Abstract] [Full Text] [Related]
12. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
Earnshaw SR, Wilson MR, Dalal AA, Chambers MG, Jhingran P, Stanford R, Mapel DW.
Respir Med; 2009 Jan 31; 103(1):12-21. PubMed ID: 19010652
[Abstract] [Full Text] [Related]
13. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.
Oba Y.
Am J Manag Care; 2009 Apr 31; 15(4):226-32. PubMed ID: 19355795
[Abstract] [Full Text] [Related]
14. Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250 μg/salmeterol 50 μg combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPD.
Dalal AA, Petersen H, Simoni-Wastila L, Blanchette CM.
J Med Econ; 2009 Apr 31; 12(4):339-47. PubMed ID: 19827993
[Abstract] [Full Text] [Related]
15. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD.
Najafzadeh M, Marra CA, Sadatsafavi M, Aaron SD, Sullivan SD, Vandemheen KL, Jones PW, Fitzgerald JM.
Thorax; 2008 Nov 31; 63(11):962-7. PubMed ID: 18621985
[Abstract] [Full Text] [Related]
16. Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids.
Friedman HS, Yawn BP.
Curr Med Res Opin; 2007 Feb 31; 23(2):427-34. PubMed ID: 17288696
[Abstract] [Full Text] [Related]
17. Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching.
Akazawa M, Biddle AK, Stearns SC.
Clin Ther; 2008 Feb 31; 30 Spec No():1003-16. PubMed ID: 18640475
[Abstract] [Full Text] [Related]
18. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.
Roberts M, Mapel D, Petersen H, Blanchette C, Ramachandran S.
J Med Econ; 2011 Feb 31; 14(6):769-76. PubMed ID: 21942463
[Abstract] [Full Text] [Related]
19. Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies.
Delea TE, Hagiwara M, Dalal AA, Stanford RH, Blanchette CM.
Curr Med Res Opin; 2009 Jan 31; 25(1):1-13. PubMed ID: 19210134
[Abstract] [Full Text] [Related]
20. Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations.
Friedman HS, Eid NS, Crespi S, Wilcox TK, Reardon G.
Clin Ther; 2009 May 31; 31(5):1056-63. PubMed ID: 19539106
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
